Chidamide

	File:Chidamide.svg
Systematic (IUPAC) name
	N-(2-Amino-5-fluorophenyl)-4-[[[1-oxo-3-(3-pyridinyl)-2-propen-1-yl]amino]methyl]-benzamide
Clinical data
Trade names	Epidaza
Identifiers
CAS Number	743420-02-2
UNII	87CIC980Y0
Chemical data
Formula	C22H19FN4O2
Molecular mass	390.4 g/mol
	SMILES NC1=C(NC(=O)C2=CC=C(CNC(=O)\C=C\C3=CN=CC=C3)C=C2)C=C(F)C=C1 ;

Chidamide (Epidaza) is an HDAC inhibitor (HDI) developed wholly in China.^[1] It was originally known as HBI-8000.^[2]

It is a benzamide HDI) and inhibits Class I HDAC1, HDAC2, HDAC3, as well as Class IIb HDAC10.^[3]

It is approved by the Chinese FDA for relapsed or refractory peripheral T-cell lymphoma (PTCL), and having orphan drug status in Japan.^[2]^{[better source needed]}

As of April 2015^[update] it is only approved in China.^[1]

It shows potential in treating pancreatic cancer.^[4]^[5]^[6]

Is NOT approved for the treatment of pancreatic cancer.

References

↑ ^1.0 ^1.1 Lua error in package.lua at line 80: module 'strict' not found.
↑ ^2.0 ^2.1 [1]
↑ HUYA Bioscience International Grants An Exclusive License For HBI-8000 In Japan And Other Asian Countries To Eisai. Feb 2016
↑ Lua error in package.lua at line 80: module 'strict' not found.
↑ Lua error in package.lua at line 80: module 'strict' not found.
↑ Lua error in package.lua at line 80: module 'strict' not found.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.